PAHCNasdaqPharmaceutical PreparationsFiscal year ends June 30

PHIBRO ANIMAL HEALTH CORP

Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 26, 2026

$39.34+0.52 (+1.34%)

Close on Oct 19, 2026

Market cap: $1.61B
P/E (TTM): 16.2
Dividend yield: 1.22%

PHIBRO ANIMAL HEALTH CORP income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-06-30	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30	FY 2020 2020-06-30	FY 2019 2019-06-30	FY 2018 2018-06-30	FY 2017 2017-06-30	FY 2016 2016-06-30	FY 2015 2015-06-30	FY 2014 2014-06-30	FY 2013 2013-06-30	FY 2012 2012-06-30
Revenue	1,518	1,296	1,018	978	942	833	800	828	820	764	752	749	692	653	654
Cost of Revenue	1,006	896	705	680	657	562	543	563	553	516	512	515	488	474	490
Gross Profit	513	400	313	298	285	271	257	265	267	248	239	233	204	179	164
Research & Development	25	24	29	24	21	18	14	12	10.00	9.44	11	9.51	8.21	6.64	7.19
Selling, General & Admin	318	289	260	226	206	197	188	181	168	150	153	146	141	122	115
General & Administrative	–	–	–	–	–	–	–	38	33	30	–	–	–	–	–
Operating Income	194	110	53	72	79	75	69	83	99	98	86	88	64	57	49
Interest Expense	46	37	23	19	13	14	15	14	14	17	17	15	33	31	31
Interest & Investment Income	–	–	–	–	–	–	–	–	–	–	–	–	0.12	0.14	0.28
Other Non-Operating Income	–	–	–	–	–	–	–	–	–	–	–	–	–	-0.15	0.40
Merger & Restructuring Charges	–	–	0.37	–	–	–	0.43	–	–	–	–	–	–	–	–
Asset Impairment Charges	–	5.33	–	–	–	–	–	–	–	–	–	–	–	–	–
Legal Settlements	3.56	2.88	0.90	–	–	–	–	–	–	–	–	–	–	–	–
Pretax Income	137	68	11	54	72	66	56	72	88	81	77	79	6.31	18	13
Income Tax Expense	38	20	8.50	21	23	12	22	17	23	16	-5.97	18	9.44	-7.04	6.14
Net Income incl. Noncontrolling Interests	100	48	2.42	33	49	54	34	–	–	–	–	–	–	–	–
Net Income	100	48	2.42	33	49	54	34	55	65	65	83	60	-3.13	25	6.98
Net Income to Common	100	48	2.42	33	49	54	34	–	–	–	–	–	–	–	–
EPS (Basic)(per share)	2.46	1.19	0.06	0.81	1.21	1.34	0.83	1.35	1.61	1.63	2.11	1.55	-0.10	0.82	0.23
EPS (Diluted)(per share)	2.43	1.19	0.06	0.81	1.21	1.34	0.83	1.35	1.61	1.61	2.07	1.51	-0.10	0.82	0.23
Shares Outstanding (Basic, Weighted)(shares)	41	41	41	41	41	40	40	0.04	0.04	0.04	0.04	39	32	0.03	0.03
Shares Outstanding (Diluted, Weighted)(shares)	41	41	41	41	41	41	41	0.04	0.04	0.04	0.04	40	32	0.03	0.03
Dividend per Share(per share)	0.48	0.48	0.48	0.48	0.48	0.48	0.48	0.46	0.40	0.40	0.40	0.40	0.82	0.10	–
EBITDA	246	156	89	106	112	107	102	111	126	124	109	109	85	76	67
Net Interest Income	–	–	–	-15	-12	-13	-13	-12	-12	-15	-17	-14	-30	36	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 33.8%
Operating margin: 12.8%
Net margin: 6.6%
Return on equity, FY2026: 29.7%

Financial strength

Current ratio: 2.96
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 19.4%

Valuation

P/E ratio: 16.2
Price to sales: 1.06
Price to book: 4.18
Dividend yield: 1.22%